BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lung FW, Lee TM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol. 2004;130:728-732. [PMID: 15365822 DOI: 10.1007/s00432-004-0605-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhou F, Zhang Y, Xu X, Luo J, Yang F, Wang L, Xie S, Sun J, Yang X. Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53. Cancer Cell Int 2018;18:118. [PMID: 30140169 DOI: 10.1186/s12935-018-0617-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Akhter N, Dar SA, Chattopadhyay S, Haque S, Anwer R, Wahid M, Jawed A, Lohani M, Mandal RK, Shukla NK, Abdul Y, Husain SA. Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population. Curr Genomics 2018;19:395-410. [PMID: 30065615 DOI: 10.2174/1389202919666171205104137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Tian X, Dai S, Sun J, Jiang S, Jiang Y. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies. Oncotarget 2017;8:1156-65. [PMID: 27901479 DOI: 10.18632/oncotarget.13589] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
4 Katkoori VR, Manne U, Chaturvedi LS, Basson MD, Haan P, Coffey D, Bumpers HL. Functional consequence of the p53 codon 72 polymorphism in colorectal cancer. Oncotarget 2017;8:76574-86. [PMID: 29100333 DOI: 10.18632/oncotarget.20580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
5 Manne U, Jadhav T, Putcha BK, Samuel T, Soni S, Shanmugam C, Suswam EA. Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective. Curr Colorectal Cancer Rep 2016;12:332-44. [PMID: 28626361 DOI: 10.1007/s11888-016-0338-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
6 Pandrangi SL, Raju Bagadi SA, Sinha NK, Kumar M, Dada R, Lakhanpal M, Soni A, Malvia S, Simon S, Chintamani C, Mohil RS, Bhatnagar D, Saxena S. Establishment and characterization of two primary breast cancer cell lines from young Indian breast cancer patients: mutation analysis. Cancer Cell Int 2014;14:14. [PMID: 24502646 DOI: 10.1186/1475-2867-14-14] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
7 Manne U, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and progression of colorectal neoplasia. Cancer Biomark. 2010;9:235-265. [PMID: 22112479 DOI: 10.3233/cbm-2011-0160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
8 Pandith AA, Khan NP, Rashid N, Azad N, Zaroo I, Hafiz A, Siddiqi MA. Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. Tumour Biol 2012;33:927-33. [PMID: 22249977 DOI: 10.1007/s13277-012-0318-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lin HY, Huang CH, Yu TJ, Wu WJ, Yang MC, Lung FW. p53 codon 72 polymorphism as a progression index for bladder cancer. Oncol Rep 2012;27:1193-9. [PMID: 22200788 DOI: 10.3892/or.2011.1610] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
10 Lin HY, Yang MC, Huang CH, Wu WJ, Yu TJ, Lung FW. Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosis. Urol Oncol 2013;31:1231-41. [PMID: 22178231 DOI: 10.1016/j.urolonc.2011.11.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Huang C, Su C, Chu J, Huang S, Pu Y, Yang H, Chung C, Wu C, Hsueh Y. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area. Toxicology and Applied Pharmacology 2011;257:349-55. [DOI: 10.1016/j.taap.2011.09.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
12 Lin HY, Huang CH, Yu TJ, Wu WJ, Yang MC, Lung FW. p53 codon 72 polymorphism was associated with vulnerability, progression, but not prognosis of bladder cancer in a Taiwanese population: an implication of structural equation modeling to manage the risks of bladder cancer. Urol Int 2011;86:355-60. [PMID: 21346315 DOI: 10.1159/000323599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, Zhang L, Xu J, Shi W, Ren YC. TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol Biol Rep 2011;38:4847-53. [PMID: 21140221 DOI: 10.1007/s11033-010-0619-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
14 Pandith AA, Shah ZA, Khan NP, Rasool R, Afroze D, Yousuf A, Wani S, Siddiqi M. Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genetics and Cytogenetics 2010;203:263-8. [DOI: 10.1016/j.cancergencyto.2010.08.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
15 Tang NP, Wu YM, Wang B, Ma J. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol. 2010;36:431-438. [PMID: 20363586 DOI: 10.1016/j.ejso.2010.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
16 Lung FW, Shu BC, Kao WT, Chen CN, Ku YC, Tzeng DS. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. BMC Med Genet 2009;10:147. [PMID: 20040103 DOI: 10.1186/1471-2350-10-147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
17 Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H, Grizzle WE, Manne U. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 2009;15:2406-16. [PMID: 19339276 DOI: 10.1158/1078-0432.CCR-08-1719] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
18 Sousa H, Santos AM, Catarino R, Pinto D, Vasconcelos A, Lopes C, Breda E, Medeiros R. Linkage of TP53 codon 72 pro/pro genotype as predictive factor for nasopharyngeal carcinoma development. Eur J Cancer Prev. 2006;15:362-366. [PMID: 16835507 DOI: 10.1097/00008469-200608000-00010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
19 Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, Giovannucci EL, Hunter DJ. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer. 2006;119:1863-1868. [PMID: 16721787 DOI: 10.1002/ijc.22057] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
20 Pérez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006; 12(9): 1426-1429 [PMID: 16552814 DOI: 10.3748/wjg.v12.i9.1426] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
21 Lin HY, Huang CH, Wu WJ, Chou YH, Fan PL, Lung FW. Mutation of the p53 tumor suppressor gene in transitional cell carcinoma of the urinary tract in Taiwan. Kaohsiung J Med Sci 2005;21:57-64. [PMID: 15825690 DOI: 10.1016/S1607-551X(09)70278-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]